2023-04-19:PtBio has started applying Zinc Finger-based genome editing technology to drug discovery!

PtBio Inc. (headquarter: Higashihiroshima in Hiroshima, CEO: Keisuke Okuhara, hereinafter "PtB"), a bio-platformer that designs biological functions, has acquired an exclusively license for a novel nuclease, “FirmCut Nuclease ND1” (ND1), developed by Hiroshima University (located in Higashi-Hiroshima City, Hiroshima Prefecture; Mitsuo Ochi, President; hereinafter "Hiroshima University"). By combining ND1 and Zinc-finger (also referred to as “ZF”), which basic patent has expired, we aim to develop a purely domestic genome editing tool called "ZF-ND1" to accelerate its medical applications.

For more details, please refer to the following URL.

<Reference links>

○Press Release (PR TIMES) *Japanese only